<Summary id="CDR0000788906" LegacyPDQID=""><SummaryMetaData><SummaryType>Supportive care</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Cognitive impairment in adult cancer survivors may include problems with memory, concentration, information processing, and executive function. </SummaryDescription><SummaryURL xref="https://www.cancer.gov/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq">Cognitive Impairment in Adults With Cancer (PDQ®)</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/about-cancer/treatment/side-effects/memory/cognitive-impairment-pdq">Cognitive Impairment in Adults With Cancer (PDQ®)</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028579">PDQ Supportive and Palliative Care Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000722010">cognitive intervention</TermRef></MainTopics><SummaryAbstract><Para id="_8">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about cognitive impairment in adults with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_9">This summary is reviewed regularly and updated as necessary by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>cognitive impairment</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Cognitive Impairment in Adults With Cancer (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Cognitive Impairment in Adults With Cancer (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Cognitive Impairment in Adults With Cancer</AltTitle><SummarySection id="_1"><Title>General Information About Cognitive Impairment in Cancer Survivors</Title><Para id="_2">Cancer survivors report more symptoms of cognitive impairment than people without a history of cancer.<Reference refidx="1"/> Formal neuropsychological testing demonstrates a range of objective cognitive deficits in some but not all survivors who report symptoms, compared with healthy controls. These deficits include the following: <Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/></Para><ItemizedList id="_117" Style="bullet"><ListItem>Impaired memory.</ListItem><ListItem>Reduced concentration.</ListItem><ListItem>Slower information processing.</ListItem><ListItem>Reduced executive function.</ListItem></ItemizedList><Para id="_118"> Subjective reports of cognitive impairment often do not correlate with the results of formal neuropsychological testing.<Reference refidx="4"/><Reference refidx="5"/> In addition, the risk factors for subjective or objective cognitive impairment—such as age, preexisting cognitive function, type of cancer, type of chemotherapy, and the natural history of the impairments—remain a matter of active investigation.</Para><Para id="_3">The oncology clinician who cares for survivors with objective or subjective cognitive impairment is advised to consider the following:</Para><ItemizedList id="_4" Style="bullet"><ListItem>Because abnormal is defined as a significant deviation from population means, formal neuropsychological testing may be insensitive to subtle changes in cognitive function since cancer diagnosis or treatment.</ListItem><ListItem>There is a strong correlation between a patient's subjective reports of cognitive impairment and decreased daily functioning <Reference refidx="6"/> or reduced quality of life.<Reference refidx="7"/></ListItem><ListItem>It is not known whether cognitive impairment influences or is a sign of psychological distress.<Reference refidx="4"/> However, one study of  226 participants (166 patients with newly diagnosed breast cancer  and 60 controls) demonstrated that patients with breast cancer  scored consistently worse than controls on cognitive tests. This decline was mediated by post-traumatic stress disorder (PTSD), indicating that PTSD may contribute in part to cognitive decline.<Reference refidx="8"/> Studies have also shown that cognitive impairment is associated with negative emotional states such as anxiety and depression,<Reference refidx="6"/><Reference refidx="9"/><Reference refidx="10"/> the personality trait of negative affectivity,<Reference refidx="11"/> and self-perceived treatment burden.<Reference refidx="9"/></ListItem><ListItem>Treatments for patients with cancer-related cognitive impairment have shown minimal to modest benefit. For clinicians, compassionate acknowledgment of a patient's concerns and a supportive approach are essential.</ListItem></ItemizedList><ReferenceSection><Citation idx="1" PMID="22548008">Jean-Pierre P, Winters PC, Ahles TA, et al.: Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study. J Oncol Pract 8 (1): 30-4, 2012.</Citation><Citation idx="2" PMID="26527785">Vardy JL, Dhillon HM, Pond GR, et al.: Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J Clin Oncol 33 (34): 4085-92, 2015.</Citation><Citation idx="3" PMID="22945857">Scherwath A, Schirmer L, Kruse M, et al.: Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 22 (7): 1509-16, 2013.</Citation><Citation idx="4" PMID="20020424">Pullens MJ, De Vries J, Roukema JA: Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19 (11): 1127-38, 2010.</Citation><Citation idx="5" PMID="22658913">Hutchinson AD, Hosking JR, Kichenadasse G, et al.: Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38 (7): 926-34, 2012.</Citation><Citation idx="6" PMID="16844416">Shilling V, Jenkins V: Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11 (1): 6-15, 2007.</Citation><Citation idx="7" PMID="22901546">Von Ah D, Habermann B, Carpenter JS, et al.: Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17 (2): 236-41, 2013.</Citation><Citation idx="8" PMID="28521364">Hermelink K, Bühner M, Sckopke P, et al.: Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. J Natl Cancer Inst 109 (10): , 2017.</Citation><Citation idx="9" PMID="20127909">Hermelink K, Küchenhoff H, Untch M, et al.: Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 19 (12): 1321-8, 2010.</Citation><Citation idx="10" PMID="17351951">Hermelink K, Untch M, Lux MP, et al.: Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109 (9): 1905-13, 2007.</Citation><Citation idx="11" PMID="2710874">Watson D, Pennebaker JW: Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol Rev 96 (2): 234-54, 1989.</Citation></ReferenceSection></SummarySection><SummarySection id="_10"><Title>Normal Cognition</Title><Para id="_11"><Strong>Cognition</Strong> is the mental process of acquiring knowledge and understanding through thought, experience, and the senses. The six domains of cognitive function summarized below were proposed in the <Emphasis>Diagnostic and Statistical Manual of Mental Disorders,</Emphasis> 5th edition, to help establish the etiology and severity of neurocognitive disorders.<Reference refidx="1"/></Para><ItemizedList id="_12" Style="bullet"><ListItem><Strong>Attention and concentration:</Strong> Ability to triage relevant information, thoughts, and actions while ignoring distractions; the ability to maintain attention for an extended period of time.</ListItem><ListItem><Strong>Executive function:</Strong> Ability to initiate and generate hypotheses, to plan, and to make decisions.</ListItem><ListItem><Strong>Information processing speed:</Strong> Ability to quickly and efficiently process information.</ListItem><ListItem><Strong>Visuospatial skill:</Strong> Ability to process and interpret visual information about where things are in space.</ListItem><ListItem><Strong>Language:</Strong> Ability to understand and communicate symbolic information, both verbally and in writing.</ListItem><ListItem><Strong>Learning and memory:</Strong> Ability to learn new information; ability to store and recall new information, in either the short term or the long term.</ListItem></ItemizedList><Para id="_13">The domains are interdependent, and any proposed taxonomy is provisional and will depend on the specific neuropsychological tests used to assess patients. Furthermore, published studies vary in terms of the cutoff for impairment and which scales are combined into a single score. While the domains reasonably capture the range of concerns experienced by people with cancer, it is important to clarify the specific impairment through a careful history and formal testing. In addition, comparisons between studies are hampered by different scales and definitions.</Para><ReferenceSection><Citation idx="1" PMID="25266297">Sachdev PS, Blacker D, Blazer DG, et al.: Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol 10 (11): 634-42, 2014.</Citation></ReferenceSection></SummarySection><SummarySection id="_14"><Title>Responding to Patient Reports of Cognitive Impairment</Title><Para id="_15">Patients with cancer may experience the following cognitive difficulties:</Para><ItemizedList id="_16" Style="bullet"><ListItem>Difficulty multitasking; must focus on one thing at a time.</ListItem><ListItem>Trouble concentrating; inability to focus on tasks.</ListItem><ListItem>Memory lapses.</ListItem><ListItem>Difficulty following instructions.</ListItem><ListItem>Decreased ability to handle personal finances.</ListItem><ListItem>Disorganized behavior or thinking.</ListItem><ListItem>Loss of initiative.</ListItem><ListItem>Difficulty remembering common words and recalling names.</ListItem><ListItem>Inability to recognize familiar objects.</ListItem><ListItem>Altered perception.</ListItem><ListItem>Difficulty finding words.</ListItem></ItemizedList><Para id="_17">Before a patient is referred for formal neuropsychological testing, the oncology clinician can perform a complete assessment of the potential contribution of medications and medical comorbidities to the patient’s experience. It is well established that preexisting illness may contribute to cognitive impairment before a patient is diagnosed with or treated for cancer.<Reference refidx="1"/> Patients who report symptoms or concerns suggestive of cognitive impairment may benefit from an evaluation of potentially reversible causes and appropriate measures. Potential contributing factors include the following:</Para><ItemizedList id="_18" Style="bullet"><ListItem>Advanced age.</ListItem><ListItem>Frailty.<Reference refidx="2"/><Reference refidx="3"/></ListItem><ListItem>Certain medications and their side effects.</ListItem><ListItem>Hormone status and menopause status.</ListItem><ListItem>Emotional distress and/or depressive symptoms and anxiety.</ListItem><ListItem>Symptoms such as pain, fatigue, and sleep disturbance.<Reference refidx="4"/>[<LOERef href="CDR0000663072" dictionary="NotSet" audience="Health professional">Level of evidence: II</LOERef>]</ListItem><ListItem>Comorbidities.</ListItem><ListItem>Use of alcohol or other agents that alter cognition.</ListItem><ListItem>Higher stage of disease, larger tumor size, and markers of tumor aggressivity  (e.g., HER2 positivity in breast cancer).<Reference refidx="5"/></ListItem><ListItem>Increased levels of C-reactive protein or other proinflammatory cytokines (e.g., interleukin 6).<Reference refidx="6"/><Reference refidx="7"/></ListItem></ItemizedList><SummarySection id="_19"><Title>Validation of the Survivor Experience</Title><Para id="_20">The experience of cognitive changes after cancer treatment has been documented in qualitative research.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/> Concerns reported by survivors include the following: <Reference refidx="8"/> </Para><ItemizedList id="_119" Style="bullet">
     <ListItem>Memory problems.</ListItem><ListItem>Inability to concentrate.</ListItem><ListItem>Decreased ability to function in daily activities, including employment.</ListItem></ItemizedList><Para id="_120">Survivors expressed frustration with health care providers' lack of acknowledgment of their cognitive changes; they also expressed the need to be informed early about the possibility of developing this problem.<Reference refidx="9"/><Reference refidx="10"/> Patients found it comforting  that subtle mental changes have been observed widely in cancer survivors and are to be expected. The least helpful response by practitioners was minimizing the changes or not taking them seriously.<Reference refidx="9"/></Para></SummarySection><SummarySection id="_21"><Title>Evaluation of Subjective Reports of Cognitive Impairment</Title><Para id="_22">As with all patient-reported symptoms and signs, a thorough evaluation will help determine the cause of cognitive impairment and potential interventions to reverse the symptoms or stabilize the patient. A focused history and physical examination can assess the following:</Para><ItemizedList id="_23" Style="bullet"><ListItem>Measures of baseline cognitive function, such as educational attainment, job-related responsibilities, and premorbid functioning.</ListItem><ListItem>Potential risk factors for cognitive impairment such as advanced age, type and stage of cancer, and treatment history, including time since last treatment and drugs used in treatment.</ListItem><ListItem>Use or misuse of prescription and over-the-counter medications and supplements.</ListItem><ListItem>Focal neurological deficits. Focal motor defects or discrete cortical defects such as aphasia or apraxia are uncommon in cancer-associated cognitive impairment.<Reference refidx="12"/></ListItem><ListItem>Signs of metastatic disease to the brain, meninges, or both.</ListItem></ItemizedList><Para id="_24">The routine use of neuroimaging is not warranted unless there are concerns about specific complications from the cancer or its treatment (e.g., metastatic cancer to the brain).</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="24841981">Mandelblatt JS, Stern RA, Luta G, et al.: Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol 32 (18): 1909-18, 2014.</Citation><Citation idx="2" PMID="25071135">Mandelblatt JS, Jacobsen PB, Ahles T: Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol 32 (24): 2617-26, 2014.</Citation><Citation idx="3" PMID="27447359">Mandelblatt JS, Clapp JD, Luta G, et al.: Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer 122 (22): 3555-3563, 2016.</Citation><Citation idx="4" PMID="36066629">Huang V, Mackin L, Kober KM, et al.: Distinct sleep disturbance and cognitive dysfunction profiles in oncology outpatients receiving chemotherapy. Support Care Cancer 30 (11): 9243-9254, 2022.</Citation><Citation idx="5" PMID="35587324">Root JC, Zhou X, Ahn J, et al.: Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study. Breast Cancer Res Treat 194 (2): 413-422, 2022.</Citation><Citation idx="6" PMID="37096888">Mandelblatt JS, Small BJ, Zhou X, et al.: Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study. Cancer 129 (15): 2409-2421, 2023.</Citation><Citation idx="7" PMID="36179271">Carroll JE, Nakamura ZM, Small BJ, et al.: Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. J Clin Oncol 41 (2): 295-306, 2023.</Citation><Citation idx="8" PMID="22201666">Myers JS: Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 39 (1): E31-40, 2012.</Citation><Citation idx="9" PMID="19760150">Boykoff N, Moieni M, Subramanian SK: Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3 (4): 223-32, 2009.</Citation><Citation idx="10" PMID="22901546">Von Ah D, Habermann B, Carpenter JS, et al.: Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17 (2): 236-41, 2013.</Citation><Citation idx="11" PMID="20500346">Munir F, Burrows J, Yarker J, et al.: Women's perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs 19 (9-10): 1362-70, 2010.</Citation><Citation idx="12" PMID="18415683">Wefel JS, Witgert ME, Meyers CA: Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 18 (2): 121-31, 2008.</Citation></ReferenceSection></SummarySection><SummarySection id="_25"><Title>Proactive Approaches to Cognitive Impairment</Title><Para id="_26">In addition to responding respectfully and compassionately to patients’ concerns about cognitive impairment, the oncology clinician faces questions on how best to inform patients about the risks of cognitive impairment and whether to screen all patients routinely or limit screening to patients at higher risk.</Para><SummarySection id="_27"><Title>Education About the Risk of Cognitive Impairment</Title><Para id="_28">In-depth interviews with cancer survivors revealed that few materials were available to educate them about cognitive problems.<Reference refidx="1"/> The amount of information desired by survivors varied from extensive to brief and general.<Reference refidx="2"/> The optimal method of information delivery was also not clear. Patients and survivors described feeling overwhelmed by the amount of written information about treatment and side effects that they received. Some patients expressed the desire to discuss their preferred method of learning with a health care provider who would provide information in a relaxed, unhurried manner.</Para><Para id="_29">One study examined the influence of priming patients to associate chemotherapy treatment with cognitive impairment. Via cancer websites, investigators recruited 150 patients with cancer who were receiving or had received chemotherapy and 86 patients who had no experience with chemotherapy to participate in a study on the effects of cancer therapies on individual patients.<Reference refidx="3"/> Volunteers were randomly assigned to receive a neutral introduction or a priming introduction that stated “some patients treated with chemotherapy experience cognitive problems.”</Para><Para id="_30">The study found an association between priming and having had chemotherapy. Patients who had chemotherapy and received the priming introduction reported higher levels of cognitive impairment than those who received the neutral introduction. No difference was found for patients not treated with chemotherapy.<Reference refidx="3"/> The volunteers were highly aware of the relationship between chemotherapy and cognitive impairment, but preexisting knowledge of that relationship had no effect
on self-reported cognitive complaints and neuropsychological test performance. These study results raise the possibility that the test environment introduced an artifact.</Para><Para id="_31">The optimal means and content for educating patients about cognitive impairment are not established. The principle of informed consent applies: the oncology clinician must inform patients of the risk in a manner that respects personal autonomy.</Para></SummarySection><SummarySection id="_32"><Title>Screening</Title><Para id="_33">No large-scale studies of routine screening for cognitive impairment in people with cancer have been published. In the clinical setting, the Mini-Mental State Exam is often used to assess for cognitive impairment <Reference refidx="4"/> but has varying sensitivities of mild cognitive impairment.<Reference refidx="5"/> The National Comprehensive Cancer Network has identified a series of questions and probes to screen for cognitive impairment and rule out other concerns (e.g., depression or sleep disturbances) that can be treated.<Reference refidx="6"/> One challenge in screening for cognitive impairment is the lack of a brief measure that can accurately assess the multiple cognitive domains.<Reference refidx="7"/> Patient-reported outcome scales (e.g., the Patient-Reported Outcomes Measurement Information System [PROMIS] 8-item and 4-point scales and the Functional Assessment of Cancer Therapy—Cognitive [FACT-Cog] version 3) might prove valuable, but further study is required. PROMIS has two scales based on the FACT-cog, including perceived cognitive impairment and perceived cognitive abilities, which measure different dimensions of cognitive impairment. </Para><Para id="_134">An additional challenge is the timing of screening activities, given the variable time to onset and the resolution of concerns without intervention for many patients.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="22201666">Myers JS: Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 39 (1): E31-40, 2012.</Citation><Citation idx="2" PMID="19760150">Boykoff N, Moieni M, Subramanian SK: Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3 (4): 223-32, 2009.</Citation><Citation idx="3" PMID="21769988">Schagen SB, Das E, Vermeulen I: Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology 21 (10): 1132-5, 2012.</Citation><Citation idx="4" PMID="1202204" MedlineID="76071605">Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (3): 189-98, 1975.</Citation><Citation idx="5" PMID="18579155">Mitchell AJ: A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res 43 (4): 411-31, 2009.</Citation><Citation idx="6" PMID="24994918">Denlinger CS, Ligibel JA, Are M, et al.: Survivorship: cognitive function, version 1.2014. J Natl Compr Canc Netw 12 (7): 976-86, 2014.</Citation><Citation idx="7" PMID="21354373">Wefel JS, Vardy J, Ahles T, et al.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12 (7): 703-8, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_34"><Title>Research Studies on the Prevalence, Risk Factors, and Natural History of Cognitive Impairment</Title><Para id="_35">This section summarizes the key findings of meta-analyses, systematic reviews, and individual studies of cognitive impairment.</Para><Para id="_36">The International Cognition and Cancer Task Force (ICCTF) has identified several  methodological differences or shortcomings in published studies:<Reference refidx="1"/><Reference refidx="2"/></Para><ItemizedList id="_37" Style="bullet"><ListItem>Whether patients enrolled in the study had presented with subjective concerns or were recruited to undergo formal testing.</ListItem><ListItem>Assessment of pretreatment cognitive impairment and interstudy differences in how baseline function was accounted for.</ListItem><ListItem>Variations in objective neuropsychological testing, including instruments selected,  definitions of cognitive domains, and definition of impairment.</ListItem></ItemizedList><Para id="_38">The ICCTF has recommended that investigators define <Emphasis>a priori</Emphasis> cognitive end points, use a core of validated neuropsychological tests, adopt common criteria for cognitive impairment, employ a longitudinal design, and use a control population.<Reference refidx="1"/><Reference refidx="2"/></Para><SummarySection id="_39"><Title>Meta-Analyses and Systematic Reviews</Title><SummarySection id="_40"><Title>Subjective cognitive concerns in patients with breast cancer</Title><Para id="_41">One group of researchers identified 27 studies of subjective cognitive impairment in patients with breast cancer that were published between 1960 and April 2009.<Reference refidx="3"/> Only eight studies were high quality. The percentage of patients reporting subjective concerns ranged from 21% to 90%. There was no correlation between subjective concerns and objective findings, and no conclusive information about timing and the contribution of disease versus treatment received.</Para><Para id="_42">Subjective concerns were related to health status, fatigue, and psychological distress. The authors pointed out that those subjective concerns may be a marker of anxiety or depression rather than objective cognitive impairment.<Reference refidx="3"/></Para><Para id="_132">In another study of 212 mostly female breast cancer survivors, fatigue and stress were more important than demographic and medical characteristics in self-reported cognitive impairment, whereas other characteristics such as age, smoking history, and number of chemotherapy cycles were more important in objective cognitive
impairment in the linear regression models. This finding emphasizes the need to address psychological problems in cancer survivors reporting cognitive impairment.<Reference refidx="4"/></Para></SummarySection><SummarySection id="_43"><Title>Relationship between subjective concerns and objective findings</Title><Para id="_44">A comprehensive screen for studies comparing rates of subjective cognitive concerns and objective cognitive impairment published between 1980 and 2012 yielded 24 studies.<Reference refidx="5"/> Only 8 of the 24 studies demonstrated a significant correlation, and 6 of these involved patients with breast cancer. The authors pointed out that the lack of correlation may be due to methodological differences (e.g., different assessment methods, different definitions of significant impairment) or the possibility that subjective concerns are a sign of psychological distress.</Para></SummarySection><SummarySection id="_45"><Title>Cognitive impairment in breast cancer survivors</Title><Para id="_46">A group of investigators performed a meta-analysis of data from studies that reported the results of neuropsychological tests in women with breast cancer who were treated for more than 6 months before the study.<Reference refidx="6"/> The investigators identified 17 studies with 807 patients; the mean time since completion of chemotherapy was 2.9 years. Weighted average effect sizes for the studied cognitive domains demonstrated modest impairment in verbal ability (effect size, –0.19; 95% confidence interval [CI], –0.30 to –0.07; <Emphasis>P</Emphasis> = .002) and visuospatial ability (effect size, –0.27; 95% CI, –0.45 to –0.08; <Emphasis>P</Emphasis> = .006).</Para></SummarySection><SummarySection id="_47"><Title>Chemotherapy and cognitive impairment in patients with cancer</Title><Para id="_48">A group of researchers calculated effect sizes based on  data from 13 high-quality studies published in  2010 and earlier.<Reference refidx="7"/> Key criteria for study inclusion were reports with primary data, statistics to allow calculation of effect sizes, and a control group; studies with patients who had psychological distress were excluded.</Para><Para id="_49">Although several domains were affected, the effect sizes  were small. The affected domains included:  </Para><ItemizedList id="_121" Style="bullet"><ListItem>Executive function (effect size, –0.27).</ListItem><ListItem>Memory (effect size, –0.21).</ListItem><ListItem>Verbal function and language skills (effect size, –0.17). </ListItem></ItemizedList><Para id="_122">Insignificant effect sizes were observed for the following:  </Para><ItemizedList id="_123" Style="bullet">
     <ListItem>Construction (the ability to draw and build).</ListItem><ListItem>Concept formation.</ListItem><ListItem>Reasoning.</ListItem><ListItem>Perception.</ListItem><ListItem>Orientation and attention.</ListItem></ItemizedList><Para id="_50">The authors noted a consistent but not universal trend of worse performance by patients who received chemotherapy compared with groups who received other types of treatment, received no treatment, or were healthy. Furthermore, longer time in treatment was associated with increased cognitive impairment, and longer time since completion of treatment was associated with cognitive improvement.<Reference refidx="7"/></Para></SummarySection><SummarySection id="_112"><Title>Subjective and objective cognitive deficits in breast cancer survivors receiving endocrine therapy</Title><Para id="_113">Researchers identified 12 high-quality studies (including 2,756 patients) published between 1966 and 2015 that examined the impact of endocrine therapy on cognitive functioning.<Reference refidx="8"/> Study eligibility criteria included all prospective and retrospective observational cohort studies and randomized controlled trials that reported the impact of endocrine therapy, including selective estrogen modulators and aromatase inhibitors, on cognitive performance. Cognitive assessments were examined in breast cancer patients over time, from baseline to 6 months to 1 year and/or 2 years.</Para><Para id="_114">Treatment with endocrine therapy was accompanied by deficits in verbal memory, verbal fluency, motor speed, attention, and working memory, but not psychomotor speed. However, findings were limited by the methodical heterogeneity of included studies and relatively short follow-up periods (3 months to 2 years).</Para><Para id="_133">In the TAILORx trial, 454 women diagnosed with breast cancer were randomly assigned to receive chemotherapy plus endocrine therapy (n = 218) or endocrine therapy alone (n = 236). They also completed the Functional Assessment of Cancer Therapy (FACT)—Cognitive Function-Perceived Cognitive Impairment (FACT-Cog PCI)  to assess perceived cognitive function at baseline (pretreatment) and at 3, 6, 12, 24, and 36 months.<Reference refidx="9"/><LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">[Level of evidence: I]</LOERef> The FACT-Cog PCI subscale is a well-known, sensitive measure of perceived cognitive impairment and has an empirical-derived, clinically meaningful change score (PCI cutoff, ˃ 0.5) to assess cognitive impairment. In this study, breast cancer survivors in both groups reported significantly poorer perceived cognitive function at 3, 6, 12, 24, and 36 months compared with baseline. Breast cancer survivors who received chemotherapy plus endocrine therapy had statistically significant and clinically meaningful change in perceived cognitive impairment at 3 and 6 months, compared with those who received endocrine therapy alone,  but this difference abated over time. The findings suggest that chemotherapy provides early but not sustained contribution to perceived cognitive impairment, indicating that  the underlying etiology may be more multifaceted than just chemotherapy use. In addition, since both groups experienced significant perceived cognitive impairment compared with baseline, more studies are needed in the clinical assessment and management of perceived cognitive impairment over the treatment trajectory.</Para><Para id="_153">In the Tamoxifen and Exemestane Adjuvant Multinational Trial, breast cancer survivors received 5 years of exemestane treatment (n = 114) or sequential treatment of 2.5 years of tamoxifen treatment, followed by 2.5 years of exemestane treatment (n = 92).<Reference refidx="10"/>  Neuropsychological performance was assessed before endocrine therapy, after 1 year (short-term [ST] follow-up), and at 5 years (long-term [LT] follow-up). A control group of 120 healthy participants were assessed with parallel intervals. After controlling for age, intelligence quotient, attrition, menopausal symptoms, anxiety and/or depression, and fatigue, the sequential group showed ST and LT decline, compared with control participants, on verbal memory (effect size [ES] = 0.26, <Emphasis>P</Emphasis> = .01; ES = 0.34, <Emphasis>P</Emphasis> =.003) and executive function (ES = 0.27, <Emphasis>P</Emphasis> =.007; ES = 0.38, <Emphasis>P</Emphasis> = .002). In addition, compared with the exemestane group, the sequential group  demonstrated ST decline on information processing speed (ES = 0.33, <Emphasis>P</Emphasis> = .01) and executive function (ES = 0.32, <Emphasis>P</Emphasis> = .01) and LT decline on verbal memory (ES = 0.33, <Emphasis>P</Emphasis> = .02). The exemestane group showed no cognitive decline compared with control participants. The apparent cognitive adverse effects of tamoxifen alone and after switching to exemestane  suggested that tamoxifen may have a carryover cognitive effect.<Reference refidx="10"/> These findings, if confirmed, suggest that tamoxifen may have more adverse cognitive effects than exemestane.</Para></SummarySection><SummarySection id="_51"><Title>Objective cognitive deficits in men with prostate cancer receiving androgen deprivation therapy (ADT)</Title><Para id="_52">Researchers identified 14 high-quality studies among 157 potentially relevant articles published between 1950 and 2012 by searching PubMed, Medline, PsycINFO, Cochrane Library, and Web of Knowledge/Science.<Reference refidx="11"/> Criteria for study inclusion were an appropriate control group, baseline measurements, and the use of objective neuropsychological tests. Eleven studies were longitudinal; the authors included three cross-sectional studies.</Para><Para id="_53">The only significant effect detected was for visuomotor ability. There were no discernible negative effects on the other domains studied, which included the following:<Reference refidx="11"/></Para><ItemizedList id="_140" Style="bullet">
     <ListItem>Attention/working memory.</ListItem><ListItem>Executive functioning.</ListItem><ListItem>Language.</ListItem><ListItem>Verbal memory.</ListItem><ListItem>Visual memory.</ListItem><ListItem>Visuospatial ability.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_54"><Title>Individual Research Studies</Title><SummarySection id="_55"><Title>Neuropsychological tests of patients with early-stage breast cancer receiving adjuvant treatment</Title><Para id="_56">Several studies are relevant to an understanding of cognitive impairment in women with early-stage breast cancer who receive chemotherapy.</Para><Para id="_57">Using a battery of neuropsychological and psychological tests, investigators assessed healthy controls and women with early-stage breast cancer who were treated with chemotherapy (n = 60) or who did not receive chemotherapy (n = 72), before treatment and again at 1, 6, and 18 months.<Reference refidx="12"/> The primary outcome of interest was processing speed. Results demonstrated that women aged 60 years or older with lower baseline cognitive reserve who received chemotherapy scored lower on processing speed than did healthy controls or women who did not receive chemotherapy. These results are consistent with results from studies of aging.<Reference refidx="13"/> There was also an effect on verbal ability that resolved by 6 months. There were no demonstrable interactions between time, age, and cognitive reserve for the following:<Reference refidx="12"/></Para><ItemizedList id="_141" Style="bullet">
     <ListItem>Verbal memory.</ListItem><ListItem>Visual memory.</ListItem><ListItem>Working memory.</ListItem><ListItem>Sorting.</ListItem><ListItem>Distractibility.</ListItem><ListItem>Reaction time.</ListItem></ItemizedList><Para id="_58">Another group of investigators performed neuropsychological assessments for 60 women younger than 66 years who had early-stage breast cancer.<Reference refidx="14"/> The subjects were tested before and after each cycle of adjuvant chemotherapy. The goal was to determine whether there was progressive decline suggesting a dose-response relationship. A control cohort of 60 healthy women matched for age and education was tested at appropriate intervals. The authors observed a dose-related decline in the following:<Reference refidx="14"/></Para><ItemizedList id="_126" Style="bullet"><ListItem>Working memory.</ListItem><ListItem>Processing speed.</ListItem><ListItem>Verbal memory.</ListItem><ListItem>Visual memory.</ListItem></ItemizedList></SummarySection><SummarySection id="_59"><Title>Subjective reports  by patients with early-stage breast cancer receiving adjuvant treatment</Title><Para id="_60">Investigators compared subjective cognitive functioning (measured by the Cognitive Failures Questionnaire) and satisfaction with subjective cognitive functioning (measured with the cognitive functioning facet of the World Health Organization Quality of Life instrument) at two  times in women with breast cancer—before chemotherapy and 3 months later—and at comparable times in women with benign breast disease.<Reference refidx="15"/> The frequency of subjective concerns did not differ, but women with breast cancer were less satisfied with their cognitive functioning. Psychological factors and diagnosis influenced satisfaction with cognitive functioning.</Para></SummarySection><SummarySection id="_61"><Title>Self-reported neurocognitive symptoms in women with breast cancer</Title><Para id="_62">Investigators conducted a longitudinal study of 581 patients with breast cancer recruited from community cancer clinics and age-matched controls.<Reference refidx="16"/> Patients and controls completed the Functional Assessment of Cancer Therapy—Cognitive Function (FACT-Cog) before receiving chemotherapy, 4 weeks postchemotherapy, and 6 months after the second assessment. Controls were tested within the same time windows as patients. Relevant findings were as follows:</Para><ItemizedList id="_63" Style="bullet"><ListItem>At baseline, patients with breast cancer had lower overall quality-of-life scores (on the FACT: General, or FACT-G) than did controls.</ListItem><ListItem>Mean FACT-G scores declined in patients postchemotherapy but remained stable in controls.</ListItem><ListItem>Almost half of the patients experienced decline in cognitive function, compared with only 10% of controls.</ListItem><ListItem>Predictors for decline on the overall FACT-Cog scale included lower reading scores, higher depression, and higher anxiety.</ListItem><ListItem>Predictors for decline in specific subscales varied.</ListItem></ItemizedList></SummarySection><SummarySection id="_64"><Title>Neuropsychological tests of patients with early-stage colon cancer</Title><Para id="_65">Researchers administered formal neuropsychological tests to 81 patients with early-stage colon cancer who were scheduled to receive oxaliplatin, leucovorin, and fluorouracil . They conducted assessments prechemotherapy (n = 81), postchemotherapy (n = 73), and 6 months after the end of the last cycle of chemotherapy (n = 54).<Reference refidx="17"/> Attention, visuomotor ability, executive function, verbal memory, and verbal learning were evaluated.</Para><Para id="_66">More than one-third of patients (37%) had cognitive impairment in processing speed and executive functioning before receiving chemotherapy. More than half of patients (56%) had a decline in verbal memory. At 6 months, 54% of patients had improved, but 33% had worsened. In an exploratory analysis, older age and fewer years of education were risk factors for cognitive impairment. Conversely, quality of life, anxiety, depression, or fatigue levels did not correlate with cognitive dysfunction.<Reference refidx="17"/></Para></SummarySection><SummarySection id="_67"><Title>Neuropsychological tests of patients with early- and advanced-stage colon cancer</Title><Para id="_68">Longitudinal changes in neuropsychological test results and patient self-reported measures of cognitive symptoms (FACT-Cog version 2) were studied in a cohort of 362 patients with colorectal cancer (289 early-stage and 73 advanced-stage) who received chemotherapy (n = 173) or did not receive chemotherapy (n = 116). Results in these patients were compared with results in a control population of 72 participants.<Reference refidx="18"/> Salient results included the following:</Para><ItemizedList id="_69" Style="bullet"><ListItem>Self-reported cognitive impairment was more common in patients who received chemotherapy (32%) than in those who did not receive chemotherapy (16%) or in controls (12.5%) (<Emphasis>P</Emphasis> = .007) at 6 months. There were no differences at 12 months.</ListItem><ListItem>Patient self-reported cognitive impairment was moderately associated with fatigue, quality of life, and anxiety/depression.</ListItem><ListItem>Correlation between neuropsychological test results and self-reported impairment was weak.</ListItem><ListItem>Based on ICCTF criteria, cognitive impairment was present in approximately 50% of patients with colorectal cancer at baseline and 6 and 12 months later, compared with approximately 15% of controls.</ListItem><ListItem>There were no differences between patients who had or had not received chemotherapy.</ListItem></ItemizedList></SummarySection><SummarySection id="_70"><Title>Neuropsychological tests of men with prostate cancer receiving ADT</Title><Para id="_71">Investigators studied 58 men with prostate cancer who received ADT at baseline and 6  and 12 months later. They compared their results to those of age-matched and education-level–matched patients with prostate cancer who did not receive ADT (n = 88) and men without prostate cancer (n = 84).<Reference refidx="19"/> The groups were similar at baseline, but at 6 and 12 months, ADT-treated men were more likely to have impaired cognitive performance according to ICCTF criteria, which combine results from individual tests. Rates of impaired cognitive performance on individual tests, however, were not significantly different at 12 months between ADT-treated patients and controls. The following factors did not moderate the effect of ADT on cognitive performance:</Para><ItemizedList id="_127" Style="bullet"><ListItem>Age.</ListItem><ListItem>Cognitive reserve.</ListItem><ListItem>Depressive symptoms.</ListItem><ListItem>Fatigue.</ListItem><ListItem>Hot flashes.</ListItem></ItemizedList></SummarySection><SummarySection id="_72"><Title>Neuropsychological tests of allogeneic stem cell transplant (SCT) recipients</Title><Para id="_73">Researchers tested 102 transplant recipients before and at 12 months after SCT.<Reference refidx="20"/> They used a battery of 14 tests to assess the following cognitive domains: </Para><ItemizedList id="_128" Style="bullet">
     <ListItem>Verbal working memory/fluency.</ListItem><ListItem>Fine motor function.</ListItem><ListItem>Visuospatial working memory.</ListItem><ListItem>Verbal learning and retrieval.</ListItem><ListItem>Reaction time.</ListItem></ItemizedList><Para id="_129">The investigators chose to report the frequency of below-normal test scores for individual tests rather than define domain-specific performance, so comparison with other studies is not possible.<Reference refidx="20"/></Para><Para id="_74">Some evidence of impairment in at least one domain was present in 47% of patients at baseline and 41% of patients at follow-up. Age and premorbid intelligence level were associated with performance. Finally, 16% of patients demonstrated a decline in cognitive function.<Reference refidx="20"/></Para></SummarySection></SummarySection><ReferenceSection><Citation idx="1" PMID="21354373">Wefel JS, Vardy J, Ahles T, et al.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12 (7): 703-8, 2011.</Citation><Citation idx="2" PMID="26344551">Joly F, Giffard B, Rigal O, et al.: Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage 50 (6): 830-41, 2015.</Citation><Citation idx="3" PMID="20020424">Pullens MJ, De Vries J, Roukema JA: Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19 (11): 1127-38, 2010.</Citation><Citation idx="4" PMID="32666213">Gutenkunst SL, Vardy JL, Dhillon HM, et al.: Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems. Support Care Cancer 29 (3): 1377-1386, 2021.</Citation><Citation idx="5" PMID="22658913">Hutchinson AD, Hosking JR, Kichenadasse G, et al.: Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38 (7): 926-34, 2012.</Citation><Citation idx="6" PMID="22927526">Jim HS, Phillips KM, Chait S, et al.: Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30 (29): 3578-87, 2012.</Citation><Citation idx="7" PMID="23219452">Hodgson KD, Hutchinson AD, Wilson CJ, et al.: A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39 (3): 297-304, 2013.</Citation><Citation idx="8" PMID="26619839">Bakoyiannis I, Tsigka EA, Perrea D, et al.: The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review. Clin Drug Investig 36 (2): 109-18, 2016.</Citation><Citation idx="9" PMID="32271671">Wagner LI, Gray RJ, Sparano JA, et al.: Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol 38 (17): 1875-1886, 2020.</Citation><Citation idx="10" PMID="37004168">Lee Meeuw Kjoe PR, Kieffer JM, Small BJ, et al.: Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer. JNCI Cancer Spectr 7 (2): , 2023.</Citation><Citation idx="11" PMID="24859915">McGinty HL, Phillips KM, Jim HS, et al.: Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer 22 (8): 2271-80, 2014.</Citation><Citation idx="12" PMID="20837957">Ahles TA, Saykin AJ, McDonald BC, et al.: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28 (29): 4434-40, 2010.</Citation><Citation idx="13" PMID="15541707">Whalley LJ, Deary IJ, Appleton CL, et al.: Cognitive reserve and the neurobiology of cognitive aging. Ageing Res Rev 3 (4): 369-82, 2004.</Citation><Citation idx="14" PMID="22936651">Collins B, MacKenzie J, Tasca GA, et al.: Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology 22 (7): 1517-27, 2013.</Citation><Citation idx="15" PMID="23109296">Pullens MJ, De Vries J, Van Warmerdam LJ, et al.: Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology 22 (8): 1783-9, 2013.</Citation><Citation idx="16" PMID="28029304">Janelsins MC, Heckler CE, Peppone LJ, et al.: Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol 35 (5): 506-514, 2017.</Citation><Citation idx="17" PMID="24535240">Cruzado JA, López-Santiago S, Martínez-Marín V, et al.: Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer 22 (7): 1815-23, 2014.</Citation><Citation idx="18" PMID="26527785">Vardy JL, Dhillon HM, Pond GR, et al.: Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J Clin Oncol 33 (34): 4085-92, 2015.</Citation><Citation idx="19" PMID="25964245">Gonzalez BD, Jim HS, Booth-Jones M, et al.: Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. J Clin Oncol 33 (18): 2021-7, 2015.</Citation><Citation idx="20" PMID="22945857">Scherwath A, Schirmer L, Kruse M, et al.: Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 22 (7): 1509-16, 2013.</Citation></ReferenceSection></SummarySection><SummarySection id="_75"><Title>Interventions for Cognitive Impairment</Title><SummarySection id="_76"><Title>Nonpharmacological Interventions</Title><Para id="_77">Evidence-based interventions to manage cognitive impairment in cancer patients and survivors have not been firmly established. Several nonpharmacological approaches have shown promise, including the following:<Reference refidx="1"/> </Para><ItemizedList id="_130" Style="bullet">
     <ListItem>Cognitive rehabilitation.</ListItem><ListItem>Exercise and physical activity.</ListItem><ListItem>Psychosocial interventions such as attention-restoring activities and meditation.</ListItem></ItemizedList><Para id="_131"> All of the interventions in Table 1  have shown some evidence of efficacy but remain active areas of investigation.</Para><Table id="_99"><Title>Table 1.  Nonpharmacological Interventions for Cognitive Impairment</Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Intervention</entry><entry>Dose</entry><entry>Comments</entry><entry>References</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1">RCT = randomized controlled trial.</entry></Row></TFoot><TBody><Row><entry><Emphasis>Cognitive rehabilitation</Emphasis></entry><entry MoreRows="3">4–96 h</entry><entry>Multiple RCTs and non-RCTs showed improvement in some components of subjective/objective cognition.</entry><entry MoreRows="1">Positive results: <Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/></entry></Row><Row><entry MoreRows="2">Included psychoeducation, compensatory training, and cognitive training.</entry><entry>1 RCT and 2 non-RCTs showed no benefit.</entry></Row><Row><entry>Most RCTs had small samples (&lt;50 participants).</entry><entry MoreRows="1">Negative results: <Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/></entry></Row><Row><entry>Wide variation in components of intervention, dose, and measures.</entry></Row><Row><entry><Emphasis>Exercise and physical activity</Emphasis></entry><entry MoreRows="2">6–65 h</entry><entry>Several small RCTs and non-RCTs showed improvement in some components of subjective/objective cognition.</entry><entry MoreRows="1">Positive results: <Reference refidx="17"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>];<Reference refidx="2"/><Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/></entry></Row><Row><entry MoreRows="1">Included various types of exercise, yoga, qigong, and tai chi.</entry><entry>2 studies showed no benefit.</entry></Row><Row><entry>Wide variation in type of movement therapy, dose, and measures.</entry><entry>Negative results: <Reference refidx="23"/><Reference refidx="24"/></entry></Row><Row><entry><Emphasis>Attention restoration and meditation</Emphasis></entry><entry MoreRows="1">12–22 h</entry><entry MoreRows="1">2 large RCTs and 3 small RCTs showed improvement in some components of subjective/objective cognition.</entry><entry MoreRows="1">Positive results: <Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/></entry></Row><Row><entry>All therapies involved quiet, focused attention in the present moment.</entry></Row></TBody></TGroup></Table><SummarySection id="_83"><Title>Cognitive rehabilitation</Title><Para id="_84">Cognitive rehabilitation has shown promise in reducing the impact of cognitive problems on cancer patients and survivors.  This approach originated to treat people with brain injuries such as stroke or traumatic brain injury, and it has been adapted for the cancer setting.<Reference refidx="30"/> Several rehabilitation approaches have been blended to varying degrees, including the following:</Para><ItemizedList id="_85" Style="bullet"><ListItem><Strong>Psychoeducation</Strong> provides useful information about brain functioning, cognitive deficits, and their consequences for daily life.<Reference refidx="4"/></ListItem><ListItem><Strong>Compensatory training</Strong> focuses on the acquisition of new behaviors and strategies to compensate for chronic dysfunction.  This intervention may include modifying or restructuring the environment by substituting external aids (such as calendars and electronic diaries) so that individuals rely less on their cognitive abilities. It may involve learning new coping strategies (such as pacing cognitive activities and minimizing distractions).<Reference refidx="8"/></ListItem><ListItem><Strong>Cognitive training</Strong> involves the use of repetitive, increasingly challenging tasks (often via computer) to improve, maintain, or restore cognitive function in the areas of attention, memory, and executive function.<Reference refidx="9"/><Reference refidx="13"/><Reference refidx="31"/></ListItem></ItemizedList><Para id="_86">The modest evidence for the efficacy of cognitive rehabilitation is based on several randomized controlled trials that used a diverse group of objective tests of neuropsychological function and subjective measures of cognitive impairment.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="11"/> Cognitive rehabilitation intervention groups showed greater improvement than controls in self-reported cognitive impairment <Reference refidx="6"/><Reference refidx="7"/> and objective neuropsychological measures of attention,<Reference refidx="6"/> memory,<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="11"/> and processing speed.<Reference refidx="11"/> Other cognitive rehabilitation intervention studies provided similar results but were limited by partial or no randomization,<Reference refidx="5"/><Reference refidx="14"/> one-group design,<Reference refidx="3"/><Reference refidx="4"/> or secondary analysis.<Reference refidx="10"/></Para></SummarySection><SummarySection id="_87"><Title>Exercise and physical activity</Title><Para id="_88">There is increasing interest in physical activity and mind-body exercise to address cognitive impairment in cancer survivors.<Reference refidx="18"/><Reference refidx="20"/><Reference refidx="23"/><Reference refidx="32"/> A systematic review of randomized controlled trials using exercise to address cognitive function in cancer survivors identified 29 potentially relevant trials that were published through 2018. Of these trials, 12 (41%) found benefit in perceived cognitive function. In addition, 3 of the 10 studies (30%) that objectively measured cognitive function found some benefit.  A number of limitations in these trials were noted; the type of physical exercise varied, and cognitive function was often not the primary outcome of interest.<Reference refidx="33"/></Para><Para id="_143">In one multicenter randomized clinical trial, 181 breast cancer survivors who had received neoadjuvant or adjuvant chemotherapy reported cognitive problems, which were confirmed by lower-than-expected performance on neuropsychological testing. Participants were randomly assigned to an exercise group or a control group.<Reference refidx="34"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>] The 6-month exercise intervention consisted of supervised aerobic exercise and strength training (2 h/wk) and Nordic/power walking (2 h/wk). Notably, two-thirds of the participants attended 80% or more of the exercise sessions, and physical fitness significantly improved for participants in the exercise group, compared with participants in the control group (peak oxygen uptake, 1.4 mL/min/kg, 95% confidence interval, 0.6–2.2). No difference was seen in the primary outcome of memory. However, significant beneficial effects were found for self-reported cognitive functioning, fatigue, quality of life, and depression. In addition, subgroup analysis indicated a positive effect of exercise on tested cognitive functioning in highly fatigued patients.</Para><Para id="_160">Similarly, the Exercise Program in Cancer and Cognition Study was a randomized controlled trial designed to determine whether 6 months of 150 minutes or more per week of moderate-intensity aerobic exercise, compared with usual-care control, improved neurocognitive function in 153 women with breast cancer receiving endocrine therapy.<Reference refidx="17"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>] Primary outcomes, assessed before baseline and within 2 weeks postintervention, included objective cognitive performance tests of processing speed, learning and memory, verbal memory, and working memory. Secondary outcomes included performance on cognitive tests of attention, executive function, and mental flexibility. Adherence to the exercise intervention was high, with 70.13% of participants who were at least 80% adherent, 67.33% who were at least 90% adherent, and 55.84% who were 100% adherent. However, cardiorespiratory fitness did not differ significantly between treatment groups from baseline to postintervention. Improvements in processing speed were noted for the exercise group compared with the usual-care group, with a significant group-by-time interaction (<Emphasis>P</Emphasis> = .041) and a trend for the main effect of time (<Emphasis>P</Emphasis> = .11) for processing speed and no change in the controls. Improvements in processing speed were associated with better intervention  adherence (<Emphasis>P</Emphasis> = .017). In addition, younger women (aged ≤60 years) had a trend for greater processing speed improvements (<Emphasis>P</Emphasis> = .06), while those with a lower educational level (≤16 years of education) had a significantly greater improvement in processing speed (<Emphasis>P</Emphasis> = .03).</Para><Para id="_144">A randomized controlled trial of qigong—a set of coordinated gentle exercises, meditation, and breathing—demonstrated improved self-reported cognitive impairment in cancer survivors after chemotherapy.<Reference refidx="20"/> Other movement studies used one-group designs,<Reference refidx="23"/> were not randomized,<Reference refidx="22"/> or were secondary analyses.<Reference refidx="19"/><Reference refidx="24"/></Para></SummarySection><SummarySection id="_89"><Title>Attention restoration</Title><Para id="_90">An intervention focused specifically on restoring and maintaining the capacity to direct attention, actively focus, and concentrate—components of cognitive function—was developed and tested in breast cancer survivors.<Reference refidx="25"/> The intervention consisted of exposure to the natural environment, including activities such as walking or sitting outdoors, tending plants or gardening, watching birds or other wildlife, and caring for pets.  Participants contracted in writing to spend 120 minutes per week engaged in one or more of these activities.  Neuropsychological tests of attention demonstrated greater improvement in the capacity to direct attention in  the group that participated in attention-restoring activities than in the control group.<Reference refidx="26"/></Para></SummarySection><SummarySection id="_91"><Title>Meditation</Title><Para id="_92">Mindfulness-based stress reduction (MBSR) is an integrative therapy that focuses on bringing attention and awareness to each moment in a nonjudgmental way. The benefits of MBSR have been evaluated in numerous studies of health conditions such as  chronic pain, anxiety, and fibromyalgia.<Reference refidx="27"/> A review of MBSR studies in cancer patients found only two randomized trials with positive results, despite a small sample size.<Reference refidx="29"/><Reference refidx="35"/> In one large, adequately powered, randomized trial in breast cancer survivors, the MBSR group showed more improvement in self-reported confusion  than did the control group at the end of the intervention period, but there were no long-term effects.<Reference refidx="27"/> No objective measures of cognitive function were used in this trial, and evidence of impairment was not a requirement for study eligibility.</Para><Para id="_93">A smaller study showed that MBSR participants experienced more positive effects on self-reported attention and working memory than did a control group. The finding was durable at 6 months.<Reference refidx="29"/> An objective measure of accuracy also showed durable improvement in the MBSR group.</Para><Para id="_94">A randomized trial of Tibetan sound meditation demonstrated improvement in objective measures of memory, processing speed, and self-reported cognitive function.<Reference refidx="28"/> Although the sample size was small, eligibility for the study required self-reported cognitive impairment.</Para></SummarySection></SummarySection><SummarySection id="_95"><Title>Pharmacological Interventions</Title><Para id="_100">Several classes of agents have been investigated as potential interventions for managing cognitive impairment. In general, the quality of study design, outcomes studied, and variations in doses and schedules of the agents prevent any firm conclusions. The agents, putative mechanisms of action, and summary of results are provided below and in <SummaryRef href="CDR0000788906#_103" url="/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq">Table 2</SummaryRef>.</Para><ItemizedList id="_101" Style="bullet">
     <ListItem><Strong>Psychostimulants:</Strong> Approved by the U.S. Food and Drug Administration primarily for attention-deficit hyperactivity disorder or sleep-wake disorders, psychostimulants are generally well tolerated. These agents have been tested in individuals with drug- or cancer therapy–induced cognitive dysfunction with varying levels of other associated symptoms.<Reference refidx="36"/><Reference refidx="37"/><Reference refidx="38"/> Seven phase II trials of different psychostimulants for treating cognitive impairment and associated symptoms were reviewed.  Not all agents showed benefit; the symptoms most likely to improve were alertness, attention, and psychomotor speed. Six trials had control arms, and one reported results in a descriptive fashion.    Also, some trials were in limited populations that may have had additional confounders such as individuals with central nervous system tumors, making results difficult to extrapolate to other patient groups.<Reference refidx="37"/><Reference refidx="38"/><Reference refidx="39"/>   Finally, the trials were underpowered, in part because of  difficulty with enrollment.</ListItem><ListItem><Strong>Erythropoietin-stimulating agents (ESAs):</Strong> The hypothesized mechanism for ESAs in the improvement of  cognitive function is the result of preclinical data demonstrating erythropoietin receptors in brain tissue providing a neuroprotective effect and preventing neuronal apoptosis.  The potential for cognitive improvement must be weighed against the risks of ESAs, which include cardiovascular and thrombotic events, the potential for causing tumor progression, and decreases in overall survival.</ListItem><ListItem><Strong>Acetylcholinesterase (AChE) inhibitors:</Strong> Donepezil, an AChE inhibitor, is approved for Alzheimer disease.  It is hypothesized that whole-brain radiation therapy (WBRT) causes neuronal injury that results in a decrease in acetylcholine.  This theory is supported clinically by similarities between WBRT cognitive dysfunction and Alzheimer disease.  The use of donepezil may increase acetylcholine levels in the brain.<Para id="_161">A large, multisite randomized controlled trial included 276 breast cancer survivors who were at a mean of 29.6 months (standard deviation = 14.2) postchemotherapy. Participants were assigned to receive either 5 mg of donepezil once daily for 6 weeks, titrated up to 10 mg once daily for 18 weeks (n = 140), or a placebo (n = 136).<Reference refidx="40"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>] At 24 weeks, the treatment groups did not differ on memory scores (Hopkins Verbal Learning Test-Revised) (donepezil mean = 25.98, placebo = 26.50; <Emphasis>P</Emphasis> = .32). In addition, there were no statistically significant differences between treatment groups at 12, 24, or 36 weeks for attention, executive function, verbal fluency, processing speed, or self-reported cognitive functioning.</Para></ListItem><ListItem><Strong>N-methyl-D-aspartate (NMDA) receptor antagonists:</Strong> By inhibiting the NMDA receptor with the antagonist memantine, radiation-induced neuronal stimulation and excitotoxicity may be reduced, preventing WBRT-induced cognitive decline.  Memantine has not been studied for reducing cognitive dysfunction in cancer patients outside of the WBRT setting.</ListItem></ItemizedList><Table id="_103"><Title>Table 2.  Agents for Managing Cognitive Impairment</Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="33.33%"/><ColSpec ColName="col2" ColNum="2" ColWidth="33.33%"/><ColSpec ColName="col3" ColNum="3" ColWidth="33.33%"/><THead><Row><entry>Agent</entry><entry>Dose</entry><entry>Comments</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1">AChE = acetylcholinesterase; bid = twice a day; ESA = erythropoietin-stimulating agent; NMDA = N-methyl-D-aspartate; qd = every day; RCT = randomized controlled trial; WBRT = whole-brain radiation therapy.</entry></Row></TFoot><TBody><Row><entry NameEnd="col3" NameSt="col1"><Strong>Psychostimulants</Strong></entry></Row><Row><entry MoreRows="1">Methylphenidate</entry><entry MoreRows="1">10–30 mg/d for ≥2 d</entry><entry>Phase II studies with varying levels of benefits for different cognitive parameters (alertness, attention, memory, psychomotor speed, and executive function).</entry></Row><Row><entry>Small trials, not always randomized, did not always meet accrual goals;  results should be interpreted with caution.<Reference refidx="36"/><Reference refidx="37"/>; <Reference refidx="39"/>[<LOERef href="CDR0000663072" dictionary="NotSet" audience="Health professional">Level of evidence: II</LOERef>]</entry></Row><Row><entry MoreRows="2">D-methylphenidate</entry><entry MoreRows="2">5–10 mg bid</entry><entry>Small, underpowered, placebo-controlled experience showed no benefit in verbal learning.</entry></Row><Row><entry>N = 57</entry></Row><Row><entry>Placebo controlled.<Reference refidx="41"/>[<LOERef href="CDR0000663072" dictionary="NotSet" audience="Health professional">Level of evidence: II</LOERef>]</entry></Row><Row><entry MoreRows="3">Modafinil</entry><entry MoreRows="3">200–400 mg/d for 4 d–6 wk</entry><entry>Phase II studies with varied trial designs.</entry></Row><Row><entry>Benefit seen in psychomotor speed, memory, executive function, and attention, with  largest study showing sustained benefit.<Reference refidx="42"/>[<LOERef href="CDR0000663072" dictionary="NotSet" audience="Health professional">Level of evidence: II</LOERef>]</entry></Row><Row><entry>Interpret with caution: accrual problems, short study duration, and inadequate power.</entry></Row><Row><entry>No benefit seen in study in which patients served as their own controls.<Reference refidx="37"/><Reference refidx="38"/><Reference refidx="43"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>]</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Strong>ESAs</Strong></entry></Row><Row><entry MoreRows="1">Erythropoietin</entry><entry MoreRows="1">40,000 U/wk</entry><entry>Multiple clinical trials demonstrated conflicting results; no intervention effect on improvement in subjective cognitive function.</entry></Row><Row><entry>Results difficult to generalize: varying assessment tools, small sample sizes, and differences in dosing and length of treatment.<Reference refidx="44"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>]; <Reference refidx="45"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>]; <Reference refidx="46"/>[<LOERef href="CDR0000663072" dictionary="NotSet" audience="Health professional">Level of evidence: II</LOERef>]; <Reference refidx="47"/>[<LOERef href="CDR0000663072" dictionary="NotSet" audience="Health professional">Level of evidence: II</LOERef>]; <Reference refidx="48"/>[<LOERef href="CDR0000663072" dictionary="NotSet" audience="Health professional">Level of evidence: II</LOERef>]; <Reference refidx="49"/></entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Strong>AChE Inhibitors</Strong></entry></Row><Row><entry MoreRows="1">Donepezil</entry><entry MoreRows="1">5 mg qd; may increase to 10 mg qd</entry><entry>Studied in patients 1–5 y postchemotherapy and &gt;6 mo post-WBRT.</entry></Row><Row><entry>Mixed results of no treatment effect and some improvement in some measures of attention, concentration, and memory in each trial.<Reference refidx="50"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>]; <Reference refidx="51"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>]; <Reference refidx="52"/>[<LOERef href="CDR0000663072" dictionary="NotSet" audience="Health professional">Level of evidence: II</LOERef>]; <Reference refidx="40"/>[<LOERef href="CDR0000663069" dictionary="NotSet" audience="Health professional">Level of evidence: I</LOERef>]</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Strong>NMDA Receptor Antagonists</Strong></entry></Row><Row><entry MoreRows="1">Memantine</entry><entry MoreRows="1">20 mg qd</entry><entry>One RCT; primary endpoint of improvement in delayed recall not statistically significant.</entry></Row><Row><entry>Treatment resulted in better cognitive function over time; delayed time to cognitive decline; and reduced rate of decline in memory, executive function, and processing speed.<Reference refidx="53"/></entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1" PMID="25689649">Von Ah D: Cognitive changes associated with cancer and cancer treatment: state of the science. Clin J Oncol Nurs 19 (1): 47-56, 2015.</Citation><Citation idx="2" PMID="17106335">Korstjens I, Mesters I, van der Peet E, et al.: Quality of life of cancer survivors after physical and psychosocial rehabilitation. Eur J Cancer Prev 15 (6): 541-7, 2006.</Citation><Citation idx="3" PMID="23955490">Ercoli LM, Castellon SA, Hunter AM, et al.: Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav 7 (4): 543-53, 2013.</Citation><Citation idx="4" PMID="17152119">Ferguson RJ, Ahles TA, Saykin AJ, et al.: Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 16 (8): 772-7, 2007.</Citation><Citation idx="5" PMID="22570263">Schuurs A, Green HJ: A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psychooncology 22 (5): 1043-9, 2013.</Citation><Citation idx="6" PMID="24012579">Cherrier MM, Anderson K, David D, et al.: A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci 93 (17): 617-22, 2013.</Citation><Citation idx="7" PMID="25759235">Ercoli LM, Petersen L, Hunter AM, et al.: Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 24 (11): 1360-7, 2015.</Citation><Citation idx="8" PMID="22271538">Ferguson RJ, McDonald BC, Rocque MA, et al.: Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 21 (2): 176-86, 2012.</Citation><Citation idx="9" PMID="23647804">Kesler S, Hadi Hosseini SM, Heckler C, et al.: Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer 13 (4): 299-306, 2013.</Citation><Citation idx="10" PMID="21251599">McDougall GJ, Becker H, Acee TW, et al.: Symptom management of affective and cognitive disturbance with a group of cancer survivors. Arch Psychiatr Nurs 25 (1): 24-35, 2011.</Citation><Citation idx="11" PMID="22918524">Von Ah D, Carpenter JS, Saykin A, et al.: Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 135 (3): 799-809, 2012.</Citation><Citation idx="12" PMID="11505244">McDougall GJ: Memory improvement program for elderly cancer survivors. Geriatr Nurs 22 (4): 185-90, 2001 Jul-Aug.</Citation><Citation idx="13" PMID="28056205">Bray VJ, Dhillon HM, Bell ML, et al.: Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. J Clin Oncol 35 (2): 217-225, 2017.</Citation><Citation idx="14" PMID="19337933">Poppelreuter M, Weis J, Bartsch HH: Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol 27 (2): 274-96, 2009.</Citation><Citation idx="15" PMID="17934527">Poppelreuter M, Weis J, Mumm A, et al.: Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 41 (1): 79-90, 2008.</Citation><Citation idx="16" PMID="21308859">Rottmann N, Dalton SO, Bidstrup PE, et al.: No improvement in distress and quality of life following psychosocial cancer rehabilitation. A randomised trial. Psychooncology 21 (5): 505-14, 2012.</Citation><Citation idx="17" PMID="38911475">Bender CM, Sereika SM, Gentry AL, et al.: Effects of aerobic exercise on neurocognitive function in postmenopausal women receiving endocrine therapy for breast cancer: The Exercise Program in Cancer and Cognition randomized controlled trial. Psychooncology 33 (2): , 2024.</Citation><Citation idx="18" PMID="22196570">Reid-Arndt SA, Matsuda S, Cox CR: Tai Chi effects on neuropsychological, emotional, and physical functioning following cancer treatment: a pilot study. Complement Ther Clin Pract 18 (1): 26-30, 2012.</Citation><Citation idx="19" PMID="25336068">Derry HM, Jaremka LM, Bennett JM, et al.: Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial. Psychooncology 24 (8): 958-66, 2015.</Citation><Citation idx="20" PMID="21688163">Oh B, Butow PN, Mullan BA, et al.: Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer 20 (6): 1235-42, 2012.</Citation><Citation idx="21" PMID="26408735">Schmidt T, Weisser B, Dürkop J, et al.: Comparing Endurance and Resistance Training with Standard Care during Chemotherapy for Patients with Primary Breast Cancer. Anticancer Res 35 (10): 5623-9, 2015.</Citation><Citation idx="22">Baumann FT, Drosselmeyer N, Leskaroski A, et al.: 12-week resistance training with breast cancer patients during chemotherapy: effects on cognitive abilities. Breast Care (Basel)  6 (2): 142-3, 2011.</Citation><Citation idx="23" PMID="12183762">Schwartz AL, Thompson JA, Masood N: Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 29 (7): E85-90, 2002.</Citation><Citation idx="24" PMID="25484317">Schmidt ME, Wiskemann J, Armbrust P, et al.: Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int J Cancer 137 (2): 471-80, 2015.</Citation><Citation idx="25" PMID="8477404">Cimprich B: Development of an intervention to restore attention in cancer patients. Cancer Nurs 16 (2): 83-92, 1993.</Citation><Citation idx="26" PMID="12886119">Cimprich B, Ronis DL: An environmental intervention to restore attention in women with newly diagnosed breast cancer. Cancer Nurs 26 (4): 284-92; quiz 293-4, 2003.</Citation><Citation idx="27" PMID="22430268">Hoffman CJ, Ersser SJ, Hopkinson JB, et al.: Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 30 (12): 1335-42, 2012.</Citation><Citation idx="28" PMID="23657969">Milbury K, Chaoul A, Biegler K, et al.: Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology 22 (10): 2354-63, 2013.</Citation><Citation idx="29" PMID="26586494">Johns SA, Von Ah D, Brown LF, et al.: Randomized controlled pilot trial of mindfulness-based stress reduction for breast and colorectal cancer survivors: effects on cancer-related cognitive impairment. J Cancer Surviv 10 (3): 437-48, 2016.</Citation><Citation idx="30" PMID="16084827">Cicerone KD, Dahlberg C, Malec JF, et al.: Evidence-based cognitive rehabilitation: updated review of the literature from 1998 through 2002. Arch Phys Med Rehabil 86 (8): 1681-92, 2005.</Citation><Citation idx="31" PMID="22119972">Von Ah D, Jansen C, Allen DH, et al.: Putting evidence into practice: evidence-based interventions for cancer and cancer treatment-related cognitive impairment. Clin J Oncol Nurs 15 (6): 607-15, 2011.</Citation><Citation idx="32" PMID="22846379">Lee CE, Kilgour A, Lau YK: Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy. BMC Cancer 12: 324, 2012.</Citation><Citation idx="33" PMID="32065236">Campbell KL, Zadravec K, Bland KA, et al.: The Effect of Exercise on Cancer-Related Cognitive Impairment and Applications for Physical Therapy: Systematic Review of Randomized Controlled Trials. Phys Ther 100 (3): 523-542, 2020.</Citation><Citation idx="34" PMID="35619188">Koevoets EW, Schagen SB, de Ruiter MB, et al.: Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study). Breast Cancer Res 24 (1): 36, 2022.</Citation><Citation idx="35" PMID="20690112">Shennan C, Payne S, Fenlon D: What is the evidence for the use of mindfulness-based interventions in cancer care? A review. Psychooncology 20 (7): 681-97, 2011.</Citation><Citation idx="36" PMID="1589233" MedlineID="92270272">Bruera E, Miller MJ, Macmillan K, et al.: Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 48 (2): 163-6, 1992.</Citation><Citation idx="37" PMID="21964738">Gehring K, Patwardhan SY, Collins R, et al.: A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 107 (1): 165-74, 2012.</Citation><Citation idx="38" PMID="23925452">Boele FW, Douw L, de Groot M, et al.: The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol 15 (10): 1420-8, 2013.</Citation><Citation idx="39" PMID="9667273">Meyers CA, Weitzner MA, Valentine AD, et al.: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16 (7): 2522-7, 1998.</Citation><Citation idx="40" PMID="38709986">Rapp SR, Dressler EV, Brown WM, et al.: Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116). J Clin Oncol 42 (21): 2546-2557, 2024.</Citation><Citation idx="41" PMID="17972110">Mar Fan HG, Clemons M, Xu W, et al.: A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16 (6): 577-83, 2008.</Citation><Citation idx="42" PMID="19309747">Kohli S, Fisher SG, Tra Y, et al.: The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115 (12): 2605-16, 2009.</Citation><Citation idx="43" PMID="19648224">Lundorff LE, Jønsson BH, Sjøgren P: Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 23 (8): 731-8, 2009.</Citation><Citation idx="44" PMID="18628159">Chang J, Couture FA, Young SD, et al.: Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Support Cancer Ther 2 (1): 52-8, 2004.</Citation><Citation idx="45" PMID="15748464">O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al.: Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 5 (6): 439-46, 2005.</Citation><Citation idx="46" PMID="18707621">Iconomou G, Koutras A, Karaivazoglou K, et al.: Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur J Cancer Care (Engl) 17 (6): 535-41, 2008.</Citation><Citation idx="47" PMID="18561284">Fan HG, Park A, Xu W, et al.: The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18 (2): 156-61, 2009.</Citation><Citation idx="48" PMID="16213740">Massa E, Madeddu C, Lusso MR, et al.: Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 57 (2): 175-82, 2006.</Citation><Citation idx="49" PMID="12533272">O'Shaughnessy JA: Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 3 (Suppl 3): S116-20, 2002.</Citation><Citation idx="50" PMID="26130292">Lawrence JA, Griffin L, Balcueva EP, et al.: A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv 10 (1): 176-84, 2016.</Citation><Citation idx="51" PMID="25897156">Rapp SR, Case LD, Peiffer A, et al.: Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. J Clin Oncol 33 (15): 1653-9, 2015.</Citation><Citation idx="52" PMID="16549835">Shaw EG, Rosdhal R, D'Agostino RB, et al.: Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 24 (9): 1415-20, 2006.</Citation><Citation idx="53" PMID="23956241">Brown PD, Pugh S, Laack NN, et al.: Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15 (10): 1429-37, 2013.</Citation></ReferenceSection></SummarySection><SummarySection id="_5"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (11/07/2024)</Title><Para id="_6">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_156"><Strong><SummaryRef href="CDR0000788906#_75" url="/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq">Interventions for Cognitive Impairment</SummaryRef></Strong></Para><Para id="_157">Revised <SummaryRef href="CDR0000788906#_99" url="/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq">Table 1</SummaryRef>, Nonpharmacological Interventions for Cognitive Impairment, to include information about exercise and physical activity (cited Bender et al. as reference 17 and level of evidence I).</Para><Para id="_158">Added <SummaryRef href="CDR0000788906#_160" url="/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq">text</SummaryRef> about the results of the Exercise Program in Cancer and Cognition Study, a randomized controlled trial designed to determine whether 6 months of 150 minutes or more per week of moderate-intensity aerobic exercise, compared with usual-care controls, improved neurocognitive function in women with breast cancer receiving endocrine therapy.</Para><Para id="_159">Added <SummaryRef href="CDR0000788906#_101" url="/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq">text</SummaryRef> about the results of a large, multisite randomized clinical trial, in which breast cancer survivors who were at a mean of 29.6 months postchemotherapy were assigned to receive either 5 mg of donepezil once daily for 6 weeks, titrated up to 10 mg once daily for 18 weeks, or a placebo (cited Rapp et al. as reference 40 and level of evidence I).</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care">PDQ Supportive and Palliative Care Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000788906#_AboutThis_1" url="/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about expert-reviewed information summary about causes and management of cognitive impairment in adults with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care">PDQ Supportive and Palliative Care Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Cognitive Impairment in Adults With Cancer are:</Para><ItemizedList Style="bullet"><ListItem>Larry D. Cripe, MD (Indiana University School of Medicine)</ListItem><ListItem>Diane Von Ah, PhD, RN, FAAN (The Ohio State University)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Supportive and Palliative Care Editorial Board uses a <SummaryRef href="CDR0000660468" url="/publications/pdq/levels-evidence/supportive-care">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Supportive and Palliative Care Editorial Board. PDQ Cognitive Impairment in Adults With Cancer. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq">https://www.cancer.gov/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 29112351]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2017-11-02</DateFirstPublished><DateLastModified>2024-11-07</DateLastModified></Summary>
